Choroid Plexus Neoplasms Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Choroid Plexus Neoplasms. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Choroid Plexus Neoplasms receives a directional score of 64/100, combining unmet need (78/100), competitive intensity (74/100) and market attractiveness (76/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

Benign or malignant tumors which arise from the choroid plexus of the ventricles of the brain. Papillomas (see PAPILLOMA, CHOROID PLEXUS) and carcinomas are the most common histologic subtypes, and tend to seed throughout the ventricular and subarachnoid spaces. Clinical features include headaches, ataxia and alterations of consciousness, primarily resulting from associated HYDROCEPHALUS. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2072; J Neurosurg 1998 Mar;88(3):521-8)

The reproducible record is Patsnap disease ID a54f4a0ac8ff4d068e5c7464e55eb846 and MeSH identifier D016545. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: Incidence of cranial and ophthalmic nerve palsy and associated risk factors in tuberculous meningitis: A systematic review and meta-regression analysis

Risk-factor prevalence highlighted substantial disease burden at presentation. Approximately 36 % had hydrocephalus and 23 % had cerebral infarction; altered sensorium approached 50 %, and about 45 % were stage III at diagnosis. Other notable features included tuberculoma and seizures (each ≈22–23 %). Continuous markers were also deranged on average (e.g., elevated CSF protein), consistent with intense meningeal inflammation (Table 2). Heterogeneity was high for most estimates, emphasizing variability in recruitment periods, diag­ nostic thresholds, and imaging practices. Subgroup analyses: time period and WHO region Time trends suggested lower CNP incidence in more recent years, declining from 56.5 % (≤2000) to 19.0 % (2021–2025); the omnibus test was significant (p = 0.0057). In contrast, ONP did not vary mean­ ingfully by period (omnibus p = 0.969) (Table 3). Regional patterns were evident: CNP was highest in SEARO (34.3 %) and lower in WPRO and EURO, with a significant overall difference (p = 0.0113). ONP showed a similar geographic gradient, with higher pooled incidence in SEARO than WPRO (p = 0.014). These patterns likely reflect differences in baseline severity, referral pathways, and access to neuroimaging across regions and eras. Meta-regression contrasts by period and region

Review source

Epidemiology evidence 2: Brain and Other Central Nervous System Tumor Statistics, 2021

Abbreviations: —­, <16 cases were diagnosed during 2013-­2017; CNS, central nervous system; NOS, not otherwise specified. aRates are per 100,000 and age-­adjusted to the 2000 US standard population. bAlthough the World Health Organization classifies pilocytic astrocytoma as a nonmalignant tumor, this histology has been historically classified as malignant for mandatory US cancer registry reporting. cIn addition to the 2012 Central Brain Tumor Registry of the United States (CBTRUS) histology group morphology codes for other neuroepithelial tumors, this category also includes a small number of choroid plexus tumors, neuronal and mixed neuronal glial tumors, and tumors of the pineal region. dIn addition to the 2012 CBTRUS histology group morphology codes for other tumors relative to the meninges, this category also includes a small number of primary melanocytic lesions. TABLE 2. (Continued) TABLE 3. Nonmalignant Brain and Other Central Nervous System Tumor Age-­Adjusted Incidence Rates by Sex and Agea (CBTRUS Data Provided by the Centers for Disease Control and Prevention’s National Program of Cancer Registries and the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program, 2013-­ 2017 [Varying]) Abbreviations: —­, <16 cases were diagnosed during 2013-­2017; CNS, central nervous system; NOS, not otherwise specified. aRates are per 100,000 and are age-­adjusted to the 2000 US standard population. bIn addition to the 2012 Central Brain Tumor Registry of the United States (CBTRUS) histology group morphology codes for other neuroepithelial tumors, this cat

Review source

Epidemiology evidence 3: Survival of European adolescents and young adults diagnosed with central nervous system tumours and comparison with younger and older age groups: EUROCARE-6 results Survival of European adolescents and young adults diagnosed with centralnervous system tumours and comparison with younger and older agegroups: EUROCARE-6 results

*including: PXA, Other gliomas, CNS embryonal tumours, Ependymoma, Medulloblastoma, Meningiomas, Germ cell tumours, AT/RT, Choroid plexus carcinoma as defined in this table ren (0–4, ). Follow- % CI 2 18.4 2 7.0 8 4.4 8 3.4 4 2.9 4 16.4 0 51.0 6 42.8 8 40.8 9 39.1 4 37.1 0 82.9 0 78.1 2 73.4 4 72.3 8 69.5 8 66.5 1 88.4 2 65.7 2 55.2 6 48.7 8 45.0 9 42.2 3 66.9 3 20.5 3 9.2 8 6.6 8 5.5 2 4.9 3 24.5 con ars) M 0–4 N§ ​ ​ ​ ​ ​ ​ 57 62 63 63 63 53 13 14 15 15 15 11 22 22 22 22 23 19 26 27 28 28 28 21 ​ ​ ​ ​ ​ ​ 16 18 18 18 18 9 12 12 12 12 12 10 ndym t in ear c yea 013 sis gliomas were the most common CNS tumour across all age groups, but within gliomas, astrocytomas, glioblastoma, and oligodendrogliomas had a higher IR in AYAs and adults compared to children (Table 1). By contrast, compared to AYA and adults, children had a higher IR for medulloblastoma, embryonal and germ cell tumours. The IRs of epen- dymomas and embryonal tumours were highest among children younger than 4 years while germ cell tumours had the highest IR in children aged 5–14 years. In AYAs, adults, and elderly, CNS tumours other than gliomas were very rare with IRs less than 3 per 1000,000 for most tumours. 3.2. Survival Table 2 reports the 1-, 2-, 3-, 4-, and 5-year RS and 5-/1-year CS for CNS tumours in different age groups. Overall, CNS tumours survival was lower in adults and elderly (40–69 and 70 + years, respectively) than in AYAs and children.

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Choroid Plexus Neoplasms, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Choroid Plexus Neoplasms thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: p53

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:38653238, PubMed:9840937). Negatively regulates cell division by controlling expression of a set of genes required for this process (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:9840937). One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492).

The mechanism anchor is TP53, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 45 registered studies.

• NCT07703605 — AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors; Not yet recruiting; Not Applicable; sponsor Shanghai Huashan Hospital; enrollment 1400.
• ChiCTR2500106101 — Assessment of Choroid Plexus Cysts and Their Relationship with Neuroinflammation in Hepatic Encephalopathy Using 3T MRI; Not yet recruiting; Not Applicable; sponsor 900th Hospital of Joint Logistics Support Force of PLA; enrollment 20.
• TCTR20240719003 — A Randomized Controlled Trial of Intramuscular Gonadotropin-Releasing Hormone (GnRH)-analogue Stimulation Test Compared to Subcutaneous Injection to Diagnose in Girls with Central Precocious Puberty; Unknown; Early Phase 1; sponsor not stated; enrollment 52.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate TP53 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Choroid Plexus Neoplasms merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Choroid Plexus Neoplasms is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.